Latest Views & News

Advanced Oncotherapy is a slam dunk short

By Tom Winnifrith | Saturday 6 August 2022

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

I should declare that I am a shareholder in this company. I bought 1 share a few years ago so that I could attend its AGM to quiz the management on the catalogue of lies they had told to investors.  Then covid struck. On a properly regulated market Advanced Oncotherapy (AVO) would have been given the order of the boot years ago, but this is AIM.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Tuesday »


Synectics – a recovery Buy?



Malcolm Stacey is Moving House

Monday »


Wood Group - a Buy (again)?



Video: Bubbles always implode

Tuesday »


Mondi – a recovery and income Buy?